[1] GRANIER C, GEY A, RONCELIN S, et al. Immunotherapy in older patients with cancer[J]. Biomed J, 2020, S2319-4170(20)30126-30128.
[2] CHANG L S, BARROSO-SOUSA R, TOLANEY S M, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints[J]. Endocr Rev, 2019, 40(1): 17-65.
[3] JANNIN A, PENEL N, LADSOUS M, et al. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders[J]. Crit Rev Oncol Hematol, 2019,141:23-35.
[4] 胡欣,陈国芳,刘超. 抗肿瘤药物对甲状腺功能的影响[J]. 国际内分泌代谢杂志, 2017, 37(1):27-31.
[5] GABORA K, PICIU A, BÄDULESCU I C, et al. Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors[J]. Drug Metab Rev, 2019, 51(4):562-569.
[6] DRUI D, ILLOUZ F, DO CAO C, et al. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors[J]. Ann Endocrinol: Paris, 2018, 79(5):569-573.
[7] DE GROOT J W, ZONNENBERG B A, PLUKKER J T, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine[J]. Clin Pharmacol Ther, 2005, 78:433-438.
[8] DESAI J, YASSA L, MARQUSEE E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors[J]. Ann Intern Med, 2006, 145:660-664.
[9] PANG R W, POON R T. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now[J]. Oncology, 2007,72(Suppl 1): 30-44.
[10]TAKADA S, HASHISHITA H, NAGAMORI S, et al.Axitinib-induced hypothyroidism as a predictor of long-term survival in patients with metastatic renal cell carcinoma[J]. Urol Int, 2019, 102(4):435-440.
[11]HIROOKA M, OCHI H, HIRAOKA A, et al. Destructive thyroiditis induced by lenvatinib in three patients with hepatocellular carcinoma[J]. Intern Med, 2019, 58(6):791-795.
[12]KOIZUMI Y, HIROOKA M, HIRAOKA A, et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma[J]. Endocr J, 2019, 66(9):787-792.
[13]AGRAWAL L, BACAL A, JAIN S, et al. Immune checkpoint inhibitors and endocrine side effects, a narrative review[J]. Postgrad Med, 2020, 132(2):206-214.
[14]LOIBL S, UNTCH M, BURCHARDI N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8):1279-1288.
[15]GARON-CZMIL J, PETITPAIN N, ROUBY F, et al. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database[J]. Fundam Clin Pharmacol, 2019, 33(2):241-249.
[16]FERRARI S M, FALLAHI P, GALETTA F, et al. Thyroid disorders induced by checkpoint inhibitors[J]. Rev Endocr Metab Disord, 2018, 19(4):325-333.
[17]LEE H, HODI F S, GIOBBIE-HURDER A, et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy[J]. Cancer Immunol Res, 2017, 5(12):1133-1140.
[18]FIDILIO E, NAVARRO-GONZÁLEZ E, ROMERO-LLUCH A R, et al. Thyroid disorders associated with immune control point inhibitors[J]. Endocrinol Diabetes Nutr, 2020, S2530-0164(20)30167-1.
[19]KIMBARA S, FUJIWARA Y, IWAMA S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab[J]. Cancer Sci, 2018, 109(11):3583-3590.
[20]DELIVANIS D A, GUSTAFSON M P, BORNSCHLEGL S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms[J]. J Clin Endocrinol Metab, 2017, 102(8):2770-2780.
[21]MAZARICO I, CAPEL I, GIMÉNEZ-PALOP O, et al. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors[J]. J Endocrinol Invest, 2019, 42(12):1443-1450.
[22]IYER P C, CABANILLAS M E, WAGUESPACK S G, et al. Immune-related thyroiditis with immune checkpoint inhibitors[J]. Thyroid, 2018, 28(10):1243-1251.
[23]DOTE S, YAMAGUCHI D, HIRA D, et al. Thyroid dysfunction related to the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab: a series of 14 cases and a descriptive study[J]. Biol Pharm Bull, 2020, 43(4):752-756.
[24]MAKITA N, MANAKA K, SATO J, et al. Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies[J]. Clin Endocrinol: Oxf, 2019, 91(1): 195-200.
[25]VASILEIADIS T, CHRISOFOS M, SAFIOLEAS M, et al. Impact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer[J]. BMC Cancer, 2019, 19(1):407.
[26]CAMPREDON P, MOULY C, LUSQUE A, et al. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients[J]. Presse Med, 2019, 48(4):e199-e207.
[27]PEIRÓ I, PALMERO R, IGLESIAS P, et al. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes[J]. Endocrine, 2019, 64(3):605-613. |
